Inflammatory Markers in Mild Cognitive Impairment: A Meta-Analysis

Journal of Alzheimer's Disease

Volumn 47, Issue 3, 2015, Pages 669-679

  Saleem, Mahwesh ^a,b   Herrmann, Nathan ^a,b   Swardfager, Walter ^a,b   Eisen, Rebecca ^a   Lanctot, Krista L ^a,b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alzheimer's disease; biological marker; cell adhesion molecules; chemokines; cytokines; fibrinogen; immunoglobulins; inflammation; meta Analysis; mild cognitive impairment

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; FIBRINOGEN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 3; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTEMATIC REVIEW; BLOOD; IMMUNOLOGY; META ANALYSIS;

HUMANS; MILD COGNITIVE IMPAIRMENT;

EID: 84938692844     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150042     Document Type: Article

References (50)

1. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 56, 303-308.
2. Lopez OL, Jagust WJ, DeKosky ST, Becker JT, Fitzpatrick A, Dulberg C, Breitner J, Lyketsos C, Jones B, Kawas C, Carlson M, Kuller LH (2003) Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: Part 1. Arch Neurol 60, 1385-1389.
3. Koyama A, OBrien J, Weuve J, Blacker D, Metti AL, Yaffe K (2013) The role of peripheral inflammatory markers in dementia and Alzheimers disease: A meta-Analysis. J Gerontol A Biol Sci Med Sci 68, 433-440.
4. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr., Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimers disease: Recommendations from the National Institute on Aging-Alzheimers Association workgroups on diagnostic guidelines for Alzheimers disease. Alzheimers Dement 7, 280-292.
5. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M, Bapineuzumab 201 Clinical Trial I (2009) A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73, 2061-2070.
6. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H (2005) Cholinesterase inhibitors for patients with Alzheimers disease: Systematic review of randomised clinical trials. BMJ 331, 321-327.
7. Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, MacArthur LH, Hall WJ, Fisher SG, Peterson DR, Haley JM, Nazar MD, Rich SA, Berlau DJ, Peltz CB, Tan MT, Kawas CH, Federoff HJ (2014) Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 20, 415-418.
8. Furney SJ, Kronenberg D, Simmons A, Guntert A, Dobson RJ, Proitsi P, Wahlund LO, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Spenger C, Lovestone S (2011) Combinatorial markers of mild cognitive impairment conversion to Alzheimers disease-cytokines and MRI measures together predict disease progression. J Alzheimers Dis 26 (Suppl 3) , 395-405.
9. Blach-Olszewska Z, Leszek J (2007) Mechanisms of overactivated innate immune system regulation in autoimmune and neurodegenerative disorders. Neuropsychiatr Dis Treat 3, 365-372.
10. Tan ZS, Beiser AS, Vasan RS, Roubenoff R, Dinarello CA, Harris TB, Benjamin EJ, Au R, Kiel DP, Wolf PA, Seshadri S (2007) Inflammatory markers and the risk of Alzheimer disease: The Framingham Study. Neurology 68, 1902-1908.
11. Forlenza OV, Diniz BS, Talib LL, Mendonça VA, Ojopi EB, Gattaz WF, Teixeira AL (2009) Increased serum IL-1β level in Alzheimers disease and mild cognitive impairment. Dement Geriatr Cogn Disord 28, 507-512.
12. Diniz BS, Teixeira AL, Ojopi EB, Talib LL, Mendonca VA, Gattaz WF, Forlenza OV (2010) Higher serum sTNFR1 level predicts conversion from mild cognitive impairment to Alzheimers disease. J Alzheimers Dis 22, 1305-1311.
13. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-Analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med 6, e1000100.
14. Noble JE, Wang L, Cerasoli E, Knight AE, Porter RA, Gray E, Howe C, Hannes E, Corbisier P, Wang J, Wu L, Altieri I, Patriarca M, Hoffman A, Resch-Genger U, Ebert B, Voigt J, Shigeri Y, Vonsky MS, Konopelko LA, Gaigalas AK, Bailey MJ (2008) An international comparability study to determine the sources of uncertainty associated with a non-competitive sandwich fluorescent ELISA. Clin Chem Lab Med 46, 1033-1045.
15. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-Analysis Stat Med 21, 1539-1558.
16. Hu WT, Holtzman DM, Fagan AM, Shaw LM, Perrin R, Arnold SE, Grossman M, Xiong C, Craig-Schapiro R, Clark CM, Pickering E, Kuhn M, Chen Y, Van Deerlin VM, McCluskey L, Elman L, Karlawish J, Chen-Plotkin A, Hurtig HI, Siderowf A, Swenson F, Lee VM, Morris JC, Trojanowski JQ, Soares H, Alzheimers Disease Neuroimaging I (2012) Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology 79, 897-905.
17. OBryant SE, Johnson L, Edwards M, Soares H, Devous MD, Ross S, Rohlfing G, Hall J, Texas Alzheimers R, Care C (2013) The link between C-reactive protein and Alzheimers disease among Mexican Americans. J Alzheimers Dis 34, 701-706.
18. Roberts RO, Geda YE, Knopman DS, Boeve BF, Christianson TJH, Pankratz VS, Kullo IJ, Tangalos EG, Ivnik RJ, Petersen RC (2009) Association of C-reactive protein with mild cognitive impairment. Alzheimers Dement 5, 398-405.
19. Leung R, Proitsi P, Simmons A, Lunnon K, Guntert A, Kronenberg D, Pritchard M, Tsolaki M, Mecocci P, Kloszewska I, Vellas B, Soininen H, Wahlund LO, Lovestone S (2013) Inflammatory proteins in plasma are associated with severity of Alzheimers disease. PLoS One 8, e64971.
20. Trollor JN, Smith E, Baune BT, Kochan NA, Campbell L, Samaras K, Crawford J, Brodaty H, Sachdev P (2011) Systemic inflammation is associated with MCI and its subtypes: The SydneyMemory and Aging Study. Dement Geriatr Cogn Disord 30, 569-578.
21. Lee KS, Chung JH, Lee KH, Shin MJ, Oh BH, Hong CH (2008) Bioplex analysis of plasma cytokines in Alzheimers disease and mild cognitive impairment. Immunol Lett 121, 105-109.
22. Llano DA, Devanarayan V, Simon AJ, Alzheimers Disease Neuroimaging I (2013) Evaluation of plasma proteomic data for Alzheimer disease state classification and for the prediction of progression from mild cognitive impairment to Alzheimer disease. Alzheimer Dis Assoc Disord 27, 233-243.
23. Marksteiner J, Kemmler G, Weiss EM, Knaus G, Ullrich C, Mechtcheriakov S, Oberbauer H, Auffinger S, Hinterholzl J, Hinterhuber H, Humpel C (2011) Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimers disease. Neurobiol Aging 32, 539-540.
24. Bermejo P, Martin-Aragon S, Benedi J, Susin C, Felici E, Gil P, Ribera JM, Villar AM (2008) Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimers disease. Immunol Lett 117, 198-202.
25. Zhao SJ, Guo CN, Wang MQ, Chen WJ, Zhao YB (2012) Serum levels of inflammation factors and cognitive performance in amnestic mild cognitive impairment: A Chinese clinical study. Cytokine 57, 221-225.
26. Kim S-M, Song J, Kim S, Han C, Park MH, Koh Y, Jo SA, Kim Y-Y (2011) Identification of peripheral inflammatory markers between normal control and Alzheimers disease. BMC Neurol 11, 51.
27. Magaki S, Mueller C, Dickson C, Kirsch W (2007) Increased production of inflammatory cytokines in mild cognitive impairment. Exp Gerontol 42, 233-240.
28. Alvarez A, Cacabelos R, Sanpedro C, Garcia-Fantini M, Aleixandre M (2007) Serum TNF-Alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease. Neurobiol Aging 28, 533-536.
29. Galimberti D, Fenoglio C, Lovati C, Venturelli E, Guidi I, Corra B, Scalabrini D, Clerici F, Mariani C, Bresolin N, Scarpini E (2006) Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimers disease. Neurobiol Aging 27, 1763-1768.
30. Hochstrasser T, Marksteiner J, Defrancesco M, Deisenhammer EA, Kemmler G, Humpel C (2011) Two Blood Monocytic Biomarkers (CCL15 and p21) Combined with the Mini-Mental State Examination discriminate Alzheimers disease patients from healthy subjects. Dement Geriatr Cogn Disord Extra 1, 297-309.
31. Porcellini E, Ianni M, Carbone I, Franceschi M, Licastro F (2013) Monocyte chemoattractant protein-1 promoter polymorphism and plasma levels in Alzheimers disease. Immun Ageing 10, 6.
32. Westin K, Buchhave P, Nielsen H, Minthon L, Janciauskiene S, Hansson O (2012) CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimers disease. PLoS One 7, e30525.
33. Galimberti D, Venturelli E, Fenoglio C, Lovati C, Guidi I, Scalabrini D, Mariani C, Bresolin N, Scarpini E (2007) IP-10 serum levels are not increased in mild cognitive impairment and Alzheimers disease. Eur J Neurol 14, e3-e4.
34. Dlugaj M, Gerwig M, Wege N, Siegrist J, Mann K, Brocker-Preus M, Dragano N, Moebus S, Jockel K-H, Bokhof B, Mohlenkamp S, Erbel R, Weimar C (2012) Elevated levels of high-sensitivity C-reactive protein are associated with mild cognitive impairment and its subtypes: Results of a population-based case-control study. J Alzheimers Dis 28, 497-501.
35. Yarchoan M, Louneva N, Xie SX, Swenson FJ, Hu W, Soares H, Trojanowski JQ, Lee VM, Kling MA, Shaw LM, Chen-Plotkin A, WolkD A, Arnold SE (2013) Association of plasma C-reactive protein levels with the diagnosis of Alzheimers disease. J Neurol Sci 333, 9-12.
36. Marksteiner J, Imarhiagbe D, Defrancesco M, Deisenhammer EA, Kemmler G, Humpel C (2014) Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimers disease and mild cognitive impairment: A pilot-study. Exp Gerontol 50, 114-121.
37. Swardfager W, Lanctot K, Rothenburg L, Wong A, Cappell J, Herrmann N (2010) A meta-Analysis of cytokines in Alzheimers disease. Biol Psychiatry 68, 930-941.
38. Ralay Ranaivo H, Craft JM, Hu W, Guo L, Wing LK, Van Eldik LJ, Watterson DM (2006) Glia as a therapeutic target: Selective suppression of human amyloidbeta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration. J Neurosci 26, 662-670.
39. Barger SW, Harmon AD (1997) Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature 388, 878-881.
40. Tarkowski E, Andreasen N, Tarkowski A, Blennow K (2003) Intrathecal inflammation precedes development of Alzheimers disease. J Neurol Neurosurg Psychiatry 74, 1200-1205.
41. Brosseron F, Krauthausen M, Kummer M, Heneka MT (2014) Body fluid cytokine levels in mild cognitive impairment and Alzheimers disease:Acomparative overview. Mol Neurobiol 50, 534-544.
42. Reed TT, Pierce WM, Markesbery WR, Butterfield DA (2009) Proteomic identification of HNE-bound proteins in early Alzheimer disease: Insights into the role of lipid peroxidation in the progression of AD. Brain Res 1274, 66-76.
43. Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256, 183-194.
44. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH (2011) The diagnosis of mild cognitive impairment due to Alzheimers disease: Recommendations from the National Institute on Aging-Alzheimers Association workgroups on diagnostic guidelines for Alzheimers disease. Alzheimers Dement 7, 270-279.
45. Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, Culliford D, Perry VH (2009) Systemic inflammation and disease progression in Alzheimer disease. Neurology 73, 768-774.
46. Holmes C, El-Okl M, Williams AL, Cunningham C, Wilcockson D, Perry VH (2003) Systemic infection, interleukin 1beta, and cognitive decline in Alzheimers disease. J Neurol Neurosurg Psychiatry 74, 788-789.
47. Libby P (2002) Inflammation in atherosclerosis. Nature 420, 868-874.
48. Hirao K, Ohnishi T, Hirata Y, Yamashita F, Mori T, Moriguchi Y, Matsuda H, Nemoto K, Imabayashi E, Yamada M, Iwamoto T, Arima K, Asada T (2005) The prediction of rapid conversion to Alzheimers disease in mild cognitive impairment using regional cerebral blood flow SPECT. Neuroimage 28, 1014-1021.
49. Elshal MF, McCoy JP (2006) Multiplex bead array assays: Performance evaluation and comparison of sensitivity to ELISA. Methods 38, 317-323.
50. Oliver JC, Bland LA, Oettinger CW, Arduino MJ, McAllister SK, Aguero SM, Favero MS (1993) Cytokine kinetics in an in vitro whole blood model following an endotoxin challenge. Lymphokine Cytokine Res 12, 115-120.